Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers,Israel |
| |
Authors: | Yaniv Lustig Neta Zuckerman Ital Nemet Nofar Atari Limor Kliker Gili Regev-Yochay Einav Sapir Orna Mor Sharon Alroy-Preis Ella Mendelson Michal Mandelboim |
| |
Affiliation: | 1.Central Virology Laboratory, Public Health Services, Ministry of Health and Sheba Medical Center, Tel Hashomer, Israel;2.Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;3.Sheba Medical Center, Tel Hashomer, Israel;4.Public Health Services, Ministry of Health, Jerusalem, Israel |
| |
Abstract: | SARS-CoV-2 Delta (B.1.617.2) variant of concern (VOC) and other VOCs are spreading in Europe. Micro-neutralisation assays with sera obtained after Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in 36 healthcare workers (31 female) demonstrated significant fold change reduction in neutralising titres compared with the original virus: Gamma (P.1) 2.3, Beta (B.1.351) 10.4, Delta 2.1 and 2.6. The reduction of the Alpha (B.1.1.7) variant was not significant. Despite being lower, remaining neutralisation capacity conferred by Comirnaty against Delta and other VOCs is probably protective. |
| |
Keywords: | COVID-19 BNT162b2 vaccination neutralizing variants B.1.617.2 (Delta) |
|
|